These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7147353)

  • 1. The LAI test in specific immune-reactivity studies of fibrocytic breast disease.
    Cavallini G; Berti G
    Tumori; 1982 Aug; 68(4):291-4. PubMed ID: 7147353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypotheses on the tumoral nature of fibrocystic mastopathy. Review of bibliographic data and experimental immunologic tests].
    Cavallini G
    Minerva Med; 1982 Sep; 73(34):2147-55. PubMed ID: 7110597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of leukocyte adherence in women with breast cancer using a variety of tissue extracts.
    Fritze D; Kaufmann M; Drings P; Fedra G
    Oncology; 1978; 35(6):242-5. PubMed ID: 370704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocyte adherence inhibition (LAI) tests in patients clinically suspected of having breast cancer using a panel of breast carcinoma extracts.
    Fritze D; Schulte-Uentrop C; Kaufmann M
    Eur J Cancer (1965); 1979 Dec; 15(12):1491-6. PubMed ID: 535612
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-tumor immunity in breast cancer evaluated by a computerized tube leukocyte adherence inhibition (LAI) assay.
    Fink A; Shani A; Feldman B; Wechsler U; Pfeffermann R; Eliraz A; Offer S; Harpaz N; Bentwich Z
    Eur J Surg Oncol; 1989 Feb; 15(1):17-9. PubMed ID: 2645173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocyte adherence inhibition: tumor specificity of cellular and serum-blocking reactions in human melanoma, breast cancer, and colorectal cancer.
    Halliday WJ; Koppi TA; Khan JM; Davis NC
    J Natl Cancer Inst; 1980 Aug; 65(2):327-35. PubMed ID: 6157045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical detection of carcinoembryonic antigen in fine-needle aspirates from patients with diverse breast diseases.
    Alexiev BA; Valkov IN; Popov AA; Marinov VS
    Diagn Cytopathol; 1993 Aug; 9(4):377-82. PubMed ID: 8261842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview: antitumor immunity in breast cancer assayed by tube leukocyte adherence inhibition.
    Flores M; Marti JH; Grosser N; MacFarlane JK; Thomson DM
    Cancer; 1977 Feb; 39(2):494-505. PubMed ID: 319891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [B cells and serum immunoglobulins in patients with breast pathology].
    Zornoza G; Hernández JL; Sanz ML; Fernández J; Goena I; Lera JM
    Rev Esp Oncol; 1981; 28(1):17-27. PubMed ID: 6984973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A correlation of erythrocyte sedimentation and plasma carcinoembryonic antigen in fibrocystic disease and carcinoma of the breast.
    Thynne GS; Greening WP
    Clin Oncol; 1980 Dec; 6(4):317-21. PubMed ID: 7460405
    [No Abstract]   [Full Text] [Related]  

  • 11. Requirement for autologous cancer extracts and lipoxygenation of arachidonic acid for human T-cell responses in leukocyte adherence inhibition and transmembrane potential change assays.
    Shenouda G; Thomson DM; MacFarlane JK
    Cancer Res; 1984 Mar; 44(3):1238-45. PubMed ID: 6420056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating breast tumour antigen-sensitive T lymphocytes in early breast cancer and high risk benign breast disease.
    Ramey WG; Hashim GA; Fitzpatrick HF
    Br J Surg; 1979 Dec; 66(12):848-52. PubMed ID: 315807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic relationship between breast carcinoma and benign breast disease as detected by the leukocyte migration inhibition assay.
    Cannon GB; McCoy JL; Jerome LJ; Reddick R; Alford C; Tinley V; Herberman RB
    J Natl Cancer Inst; 1978 Nov; 61(5):1181-6. PubMed ID: 280705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sera from breast cancer patients contain an IgA antibody to a breast cyst fluid component.
    Witkin SS; Richards JM; Bongiovanni AM; Breed CN; Day NK
    Clin Immunol Immunopathol; 1982 May; 23(2):358-65. PubMed ID: 6286196
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of leukocyte migration by human breast-cancer-associated antigens.
    Kadish AS; Marcus DM; Bloom BR
    Int J Cancer; 1976 Nov; 18(5):581-6. PubMed ID: 62721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking of the response by human T-lymphocytes to extracts of autologous cancer by monoclonal antibody to Class-I major histocompatibility complex gene products in the leukocyte adherence inhibition assay.
    Shenouda G; Thomson DM
    Cancer Res; 1984 Jul; 44(7):2762-8. PubMed ID: 6609766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence in advanced cancer of an activated leukocyte state to explain the reversible defect in transmembrane signaling and leukocyte adherence inhibition to extracts of cancer.
    Shenouda G; Thomson DM
    Clin Immunol Immunopathol; 1984 Aug; 32(2):212-23. PubMed ID: 6375921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of leukocyte adherence by 3-M potassium chloride extracts of human colorectal tumors.
    Ichiki AT; Quirin YP; Collmann IR; Sonoda T; Krauss S
    J Natl Cancer Inst; 1980 Mar; 64(3):419-23. PubMed ID: 6986496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral antitumor immune responses in patients with breast cancer measured with the leukocyte adherence inhibition technique.
    Kotlar HK; Sanner T
    J Natl Cancer Inst; 1981 Feb; 66(2):265-71. PubMed ID: 7005505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology.
    Pastides H; Kelsey JL; LiVolsi VA; Holford TR; Fischer DB; Goldenberg IS
    J Natl Cancer Inst; 1983 Jul; 71(1):5-9. PubMed ID: 6575209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.